Inovio Pharmaceuticals Inc vs Teucrium Wheat Fund — how do they compare? Inovio Pharmaceuticals Inc trades at $1.12 (market cap $91.32M), while Teucrium Wheat Fund trades at $25.18. The key difference: Teucrium Wheat Fund is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| INO | WEAT | |
|---|---|---|
Market Cap | $91.32M | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $2.87 | $25.49 |
52-Week Low | $1.05 | $19.88 |
Enterprise Value | $62.34M | — |
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.12, unchanged on the day, with a bearish technical signal from moving averages. The company reported minimal revenue of $65,340 in 2025 and a net loss of $84.95 million, though it has beaten EPS estimates for three consecutive quarters. Recent news highlights an active FDA review for INO-3107 with a PDUFA date of October 30, 2026, alongside shareholder litigation investigations.
The outlook hinges on the binary FDA decision for INO-3107, offering significant upside if approved, but the stock carries high risk due to persistent losses, negative cash flow, and legal overhangs. Analyst consensus is cautiously optimistic with a 52.95% buy rating, but fundamental weaknesses necessitate careful risk assessment.
No Aura AI signal available yet.
Trailing returns across standard periods
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →WEAT is a commodity ETF that provides exposure to the price of wheat futures. It employs a laddered strategy across multiple benchmark contracts to mitigate the effects of contango and roll costs inherent in agricultural futures trading.
Read more on WEAT →